Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity.

Chhabra KR, Gencerliler N, Orandi BJ, Wang VH, Kozato A, Surapaneni A, Grams M, Mukhopadhyay A, Shin JI, Ren-Fielding C, Parikh M, Zhang DS

Obesity (Silver Spring, Md.)6 May 2026

PMID42089543DOI10.1002/oby.70209PepBankPUB-42089543

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyOther
In patients with obesity and type 2 diabetes, semaglutide was associated with higher 3-year out-of-pocket costs than sleeve gastrectomy or gastric bypass.
In plain wordsIn patients with obesity and type 2 diabetes, semaglutide was linked to higher out-of-pocket costs over 3 years than either bariatric surgery.
Peptide
Semaglutide
Outcome
Increase3-year out-of-pocket costs
Study
n = 6,748
Comparator
Sleeve gastrectomy; gastric bypass
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Measurements
Out-of-pocket cost
7752 $
semaglutide
Out-of-pocket cost
5980 $
sleeve gastrectomy
Out-of-pocket cost
6591 $
gastric bypass
Source sentences
Summary
semaglutide was associated with the highest 3-year OOP costs ($7752 vs. $5980 [sleeve gastrectomy] vs. $6591 [gastric bypass], p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
Using MarketScan insurance claims of patients with BMI ≥ 35 and T2D from 2016 to 2021, we examined associations between choice of semaglutide, sleeve gastrectomy, or gastric bypass; 3-year health care spending (out-of-pocket [OOP] and total); and clinical outcomes (ED visits, hospital admissions, an…
Report a problemFND-4208954301
02HumanObservational studyOther
In patients with obesity and type 2 diabetes, 3-year total health care spending with semaglutide did not differ significantly from sleeve gastrectomy or gastric bypass.
In plain wordsIn patients with obesity and type 2 diabetes, total 3-year health care spending with semaglutide was not clearly different from either bariatric surgery.
Peptide
Semaglutide
Outcome
No significant change3-year total health care spending
Study
n = 6,748
Comparator
Sleeve gastrectomy; gastric bypass
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Source sentences
Summary
but total spending was not statistically different across the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Using MarketScan insurance claims of patients with BMI ≥ 35 and T2D from 2016 to 2021, we examined associations between choice of semaglutide, sleeve gastrectomy, or gastric bypass; 3-year health care spending (out-of-pocket [OOP] and total); and clinical outcomes (ED visits, hospital admissions, an…
Report a problemFND-4208954302
03HumanObservational studyOther
In patients with obesity and type 2 diabetes, semaglutide was associated with fewer emergency department visits than gastric bypass.
In plain wordsIn patients with obesity and type 2 diabetes, semaglutide was linked to fewer emergency visits than gastric bypass.
Peptide
Semaglutide
Outcome
DecreaseED visits versus gastric bypass
Study
n: not reported in source
Comparator
Gastric bypass
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Measurements
Hazard ratio, gastric bypass vs semaglutide
1.36
ED visits
Source sentences
Summary
Relative to semaglutide, the gastric bypass group showed higher observed ED visits (hazard ratio relative to semaglutide [95% CI]: 1.36 [1.28-1.45]) and inpatient admissions (1.25 [1.13-1.37]) and fewer MACE (0.71 [0.59-0.88]).
1 context sentence(design, population, supporting numbers)
Summary · context
Using MarketScan insurance claims of patients with BMI ≥ 35 and T2D from 2016 to 2021, we examined associations between choice of semaglutide, sleeve gastrectomy, or gastric bypass; 3-year health care spending (out-of-pocket [OOP] and total); and clinical outcomes (ED visits, hospital admissions, an…
Report a problemFND-4208954303
04HumanObservational studyOther
In patients with obesity and type 2 diabetes, semaglutide was associated with fewer inpatient admissions than gastric bypass.
In plain wordsIn patients with obesity and type 2 diabetes, semaglutide was linked to fewer hospital admissions than gastric bypass.
Peptide
Semaglutide
Outcome
DecreaseInpatient admissions versus gastric bypass
Study
n: not reported in source
Comparator
Gastric bypass
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Measurements
Hazard ratio, gastric bypass vs semaglutide
1.25
inpatient admissions
Source sentences
Summary
Relative to semaglutide, the gastric bypass group showed higher observed ED visits (hazard ratio relative to semaglutide [95% CI]: 1.36 [1.28-1.45]) and inpatient admissions (1.25 [1.13-1.37]) and fewer MACE (0.71 [0.59-0.88]).
1 context sentence(design, population, supporting numbers)
Summary · context
Using MarketScan insurance claims of patients with BMI ≥ 35 and T2D from 2016 to 2021, we examined associations between choice of semaglutide, sleeve gastrectomy, or gastric bypass; 3-year health care spending (out-of-pocket [OOP] and total); and clinical outcomes (ED visits, hospital admissions, an…
Report a problemFND-4208954304
05HumanObservational studyEfficacy outcome
In patients with obesity and type 2 diabetes, semaglutide was associated with more major adverse cardiovascular events than gastric bypass.
In plain wordsIn patients with obesity and type 2 diabetes, semaglutide was linked to more major heart and blood vessel events than gastric bypass.
Peptide
Semaglutide
Outcome
IncreaseMACE versus gastric bypass
Study
n: not reported in source
Comparator
Gastric bypass
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Measurements
Hazard ratio, gastric bypass vs semaglutide
0.71
MACE
Source sentences
Summary
Relative to semaglutide, the gastric bypass group showed higher observed ED visits (hazard ratio relative to semaglutide [95% CI]: 1.36 [1.28-1.45]) and inpatient admissions (1.25 [1.13-1.37]) and fewer MACE (0.71 [0.59-0.88]).
1 context sentence(design, population, supporting numbers)
Summary · context
Using MarketScan insurance claims of patients with BMI ≥ 35 and T2D from 2016 to 2021, we examined associations between choice of semaglutide, sleeve gastrectomy, or gastric bypass; 3-year health care spending (out-of-pocket [OOP] and total); and clinical outcomes (ED visits, hospital admissions, an…
Report a problemFND-4208954305
06HumanObservational studyOther
In patients with obesity and type 2 diabetes, semaglutide was associated with more long-term admissions than sleeve gastrectomy.
In plain wordsIn patients with obesity and type 2 diabetes, semaglutide was linked to more long-term hospital admissions than sleeve gastrectomy.
Peptide
Semaglutide
Outcome
IncreaseLong-term admissions versus sleeve gastrectomy
Study
n: not reported in source
Comparator
Sleeve gastrectomy
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Measurements
Hazard ratio, sleeve gastrectomy vs semaglutide
0.79
long-term admissions
Source sentences
Summary
Sleeve gastrectomy was associated with fewer long-term admissions (0.79 [0.72-0.86]
1 context sentence(design, population, supporting numbers)
Summary · context
Using MarketScan insurance claims of patients with BMI ≥ 35 and T2D from 2016 to 2021, we examined associations between choice of semaglutide, sleeve gastrectomy, or gastric bypass; 3-year health care spending (out-of-pocket [OOP] and total); and clinical outcomes (ED visits, hospital admissions, an…
Report a problemFND-4208954306
07HumanObservational studyEfficacy outcome
In patients with obesity and type 2 diabetes, semaglutide was associated with more major adverse cardiovascular events than sleeve gastrectomy.
In plain wordsIn patients with obesity and type 2 diabetes, semaglutide was linked to more major heart and blood vessel events than sleeve gastrectomy.
Peptide
Semaglutide
Outcome
IncreaseMACE versus sleeve gastrectomy
Study
n: not reported in source
Comparator
Sleeve gastrectomy
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Measurements
Hazard ratio, sleeve gastrectomy vs semaglutide
0.79
MACE
Source sentences
Summary
Sleeve gastrectomy was associated with fewer long-term admissions (0.79 [0.72-0.86]) and MACE (0.79 [0.66-0.93]).
1 context sentence(design, population, supporting numbers)
Summary · context
Using MarketScan insurance claims of patients with BMI ≥ 35 and T2D from 2016 to 2021, we examined associations between choice of semaglutide, sleeve gastrectomy, or gastric bypass; 3-year health care spending (out-of-pocket [OOP] and total); and clinical outcomes (ED visits, hospital admissions, an…
Report a problemFND-4208954307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.